During the past decades, anticancer immunotherapy has evolved from a promising
therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now …

Dendritic-cells (DCs) have received considerable attention as potential targets for the
development of anticancer vaccines. DC-based anticancer vaccination relies on patient …

Objectives: An impaired host immunity might concur in determining the dismal prognosis of
patients with pancreatic cancer (PC). Our aim was to ascertain whether the …

Dendritic cell (DC)-based vaccines against cancer have been extensively developed over
the past two decades. Typically DC-based cancer immunotherapy entails loading patient …

Dendritic cells (DCs) occupy a central position in the immune system, orchestrating a wide
repertoire of responses that span from the development of self-tolerance to the elicitation of …

Dendritic cells (DCs) occupy a privileged position at the interface between innate and
adaptive immunity, orchestrating a large panel of responses to both physiological and …

Pancreatic cancer is a highly aggressive and lethal cancer characterized by high
invasiveness, local and extensive dissemination at time of diagnosis and resistance to …

Regulatory T cells (Treg) mediate tolerance towards self‐antigens by suppression of innate
and adaptive immunity. In cancer patients, tumor‐infiltrating FoxP3+ Treg suppress local anti …

Ag presentation by dendritic cells (DC) is essential to effective antitumor T cell responses in
cancer patients. Depending on their origin, maturation state, and the ambient cytokine …

Pancreatic cancer is an extremely aggressive malignancy with a dismal prognosis. Cancer
patients and tumor-bearing mice have multiple immunoregulatory subsets including …